PDF(Pubmed)
Abstract：
Breast cancer is one of the most diagnosed solid cancers globally. Extensive research has been going on for decades to meet the challenges of treating solid tumors with selective compounds. This article aims to summarize the therapeutic agents which are either being used or are currently under approval for use in the treatment or mitigation of breast cancer by the US FDA, to date. A structured search of bibliographic databases for previously published peer-reviewed research papers on registered molecules was explored and data was sorted in terms of various categories of drugs used in first line/adjuvant therapy for different stages of breast cancer. We included more than 300 peer-reviewed papers, including both research and reviews articles, in order to provide readers an useful comprehensive information. A list of 39 drugs are discussed along with their current status, dose protocols, mechanism of action, pharmacokinetics, possible side effects, and marketed formulations. Another interesting aspect of the article included focusing on novel formulations of these drugs which are currently in clinical trials or in the process of approval. This exhaustive review thus shall be a one-stop solution for researchers who are working in the areas of formulation development for these drugs.
摘要：
乳腺癌是全球诊断最多的实体癌之一。几十年来，广泛的研究一直在进行，以应对用选择性化合物治疗实体瘤的挑战。本文旨在总结美国FDA正在使用或目前批准用于治疗或缓解乳腺癌的治疗剂，到目前为止。探索了以前发表的关于注册分子的同行评审研究论文的书目数据库的结构化搜索，并根据用于乳腺癌不同阶段的一线/辅助治疗的各种药物类别对数据进行了分类。我们收录了300多篇同行评审的论文，包括研究和评论文章，从而为读者提供有用的综合信息。讨论了39种药物的清单及其现状，剂量方案，作用机制,药代动力学，可能的副作用,和市售配方。文章的另一个有趣的方面包括关注这些药物的新制剂，这些药物目前正在临床试验或批准过程中。因此，对于在这些药物的制剂开发领域工作的研究人员来说，这项详尽的审查将是一站式解决方案。
